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Abstract: Selenium (Se) is an essential trace element involved in different physiological 
functions of the human body and plays a role in cancer prevention and treatment. Induction 
of apoptosis is considered an important cellular event that can account for the cancer 
preventive effects of Se. The mechanisms of Se-induced apoptosis are associated with the 
chemical forms of Se and their metabolism as well as the type of cancer studied. So, some 
selenocompounds, such as SeO2 involve the activation of caspase-3 while sodium selenite 
induces apoptosis in the absence of the activation of caspases. Modulation of mitochondrial 
functions has been reported to play a key role in the regulation of apoptosis and also to be 
one of the targets of Se compounds. Other mechanisms for apoptosis induction are the 
modulation of glutathione and reactive oxygen species levels, which may function as 
intracellular messengers to regulate signaling pathways, or the regulation of kinase, among 
others. Emerging evidence indicates the overlaps between the apoptosis and other types of 
cell death such as autophagy. In this review we report different processes of cell death 
induced by Se compounds in cancer treatment and prevention. 
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1. Introduction 
Selenium (Se) is an oligoelement with essential biological functions and belongs to the most 
extensively studied chemopreventive compounds [1,2]. Foods (cereals, grains, vegetables) contain 
diverse amounts and chemical forms of Se [3]. An adequate Se intake has been estimated at 50 μg/day 
with toxic levels being estimated to occur with intakes of the order of 350–700 μg/day [4]. Se is 
important for many cellular processes, because it is a component of several selenoproteins with 
preventive function of some forms of cancer [5,6]. Se supplementation with low doses seems to be 
beneficial not only for cancer prevention, but it can positively influence many other functions in an 
organism by reducing inflammations, heart diseases and regulating the blood pressure [7]. Effectiveness 
of Se compounds as chemopreventive agents in vivo is correlated with their abilities to effect the 
regulation of the cell cycle, to stimulate apoptosis and to inhibit tumor cell migration and invasion  
in vitro [8]. The cell cycle is a conserved mechanism by which eukaryotic cells replicate themselves. 
The eukaryotic cell cycle is divided into four major phases as follows: the G1 phase before DNA 
replication, the periods of DNA synthesis (S phase), the G2 phase before cell division and cell division 
(M phase). On the other hand, apoptosis is also a highly conserved mechanism by which eukaryotic 
cells commit suicide and enable an organism to eliminate unwanted and defective cells during normal 
development, turnover and pathological conditions. In humans and animals, cell proliferation and 
death must be regulated to maintain tissue homeostasis. Apoptosis induced by supranutritional doses of 
this compound was described in various types of neoplastic cells, including prostate, colon and liver 
cancer, leukemia and lymphoma [7]. There are several proposed mechanisms to explain the effect of 
Se on cell cycle and apoptosis and it has been well recognized that Se plays a key role in these 
processes but mechanisms for Se action are very complex and not fully understood. They involve 
protein kinases signaling, activation of caspases, p53 phosphorylation and reactive oxygen species 
(ROS) generation [9–14]. Besides, it is widely recognized that the effectiveness of Se compounds as 
chemopreventive and anticancer agents is correlated with their chemical form and doses. The chemical 
structure dependence is exemplified in the contradictory results of two clinical trials using 200 μg of 
Se supplementation per day in the prevention of cancer. In the Nutritional Prevention of Cancer (NPC) 
Trial, supplementation of Se enriched yeast was shown to reduce the incidence of a number of  
cancers [15] including prostate cancer [16], whereas the Se and Vitamin E Cancer Prevention Trial 
(SELECT), that used selenomethionine (SeMet) (Figure 1), major component of Se yeast, ceased early 
as there was no reduction in the incidence of prostate cancer [17]. Therefore, other components of Se 
yeast, e.g., methylselenocysteine (MeSeCys) may be contributing to the overall efficacy of Se yeast 
used in NPC trial. So, two similar compounds, i.e., MeSeCys and SeMet can have disparate efficacies 
as anticancer agents. The reason behind this fact is the difference in the speciation of Se in cells treated 
with MeSeCys or SeMet, mainly in the potential redox-altering capabilities of the metabolites of 
MeSeCys as evidenced by the presence of diselenides [18]. Tapiero et al. [19] have reported that 
metabolites of Se compounds have been shown to induce ROS, which in turn can induce oxidative 
modifications and DNA stand breaks. Studies have focused on Se-induced stress responses in various 
cultured cancer cells, from which it is suggested that much of the role of Se in cancer prevention is 
attributable to ROS-induced apoptosis or cell cycle arrest in cancer cells. Consistent with this notion, it 
has been shown that Se-induced apoptosis in cancer cells can be suppressed by antioxidants and is 
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p53-dependent. Furthermore, Se can sensitize cancer cells to other apoptotic inducers, including tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) and doxorubicin. The observation that Se 
specifically induces senescence response in non-cancerous cells suggests a cost-effective scenario by 
which tumorigenesis can be stifled at the very beginning in individuals who consume Se with a cancer 
prevention perspective. In addition, prior to occurrence of apoptosis, Se compounds alter the 
expression and/or activities of signaling molecules, mitochondria associated factors, transcriptional 
factors, tumor suppressor genes and cellular reduced glutathione. Among the metabolites of Se 
derivatives it was demonstrated that methylselenol metabolite pool has many desirable attributes of 
chemoprevention whereas the hydrogenselenide pool with excess of selenoprotein synthesis can lead 
to DNA single-strand breaks [20].  
Figure 1. Selenomethionine and methylselenocysteine. 
 
On the other hand, there are emerging evidences that cell death caused by Se and Se compounds can 
occur not only by apoptotic pathway but can also proceed by non-apoptotic modes such as autophagy, 
necrosis, mitotic catastrophe or combinations thereof, because there are overlaps among them [21]. 
This has been demonstrated in NB4 cells treated with sodium selenite that suppressed autophagy and 
increased apoptosis through phosphoinositide-3-kinase (PI3K)/Akt [22]. In addition, Suzuki et al. [23] 
have examined the contribution of autophagy to the mechanism of apoptosis caused by SeMet in A549 
lung carcinoma cells. They demonstrated that the Akt/mammalian target of rapamycin (mTOR)/ROS 
pathway was affected but no evidences were found for autophagy. This article covers recent reports on 
various processes by which Se compounds cause cancer cell death. A classification of Se compounds 
discussed in this review article is presented in Table 1.  
Table 1. Classification of Se compounds based on structural features. 
Selenoaminoacids 
Selenomethionine (SeMet); Methylselenocysteine (MeSeCys); Selenocystamine; Selenocysteine (SeCys) 
Se-heterocyclic compounds 
1,3-Selenazolin-4-one derivatives; 2,5-Bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole 
(D-501036); 2-Phenyl-1,2-benzisoselenazol-3(2H)-one (ebselen); 1,2-[Bis(1,2-benzisoselenazolone-3-(2H)-
ketone)]ethane (BBSKE); 2-Buthylselenazolidine-4-(R)-carboxylic acid (BSCA); 2-Cyclohexylselenazolidine-
4-(R)-carboxylic acid (ChSCA) 
Selenocyanates 
1-4-phenylenebis(methylene)selenocyanate (p-XSC); Isatin analogs; Diphenylmethylselenocyanate; 
TMZ-Se; 5-phenylcarbamoylpentyl selenocyanide (SelSA-2) 
Isoselenocyanates 
4-Phenylbutylisoselenocyanate (ISC-4) 
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Table 1. Cont. 
Diselenides 
Diselenodipropionic acid (DSePA); Bis(4-aminophenyl)diselenide; 2-Selenium-bridged β-cyclodextrin 
(2-SeCD); Bis(5-phenylcarbamoylpentyl) diselenide (SelSA-1) 
Selenides 
Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe); Methylimidoselenocarbamates; 
5-Phenylselenyl-methyl-2'-deoxyuridine (PhSe-T); 5-Methylselenyl-methyl-2'-deoxyuridine (MeSe-T); β-
selenium amine derivatives 
Se(IV) compounds 
Sodium selenite (Na2SeO3); Methylseleninic acid (MSA); Selenous acid; Selenium dioxide (SeO2) 
2. Apoptosis and Kinases Modulation 
Recent reports have shown that Se compounds are able to induce tumor cell apoptosis through 
distinct mechanisms according to cell type and compound pattern. It is known that several protein 
kinase pathways play essential roles in mediating mitogenic and antiapoptotic signals and can regulate 
cell proliferation and survival. The mechanism of apoptosis induction of Se compounds is variable 
depending on their structure, metabolism and type of cell line studied. So, methylselenol, produced by 
metabolism of SeMet inhibits extracellular signal-regulated kinase (ERK1/2) pathway activation in 
fibrosarcoma tumor cells HT1080 [24]. However, tumor inhibition by sodium selenite (Figure 2) in 
human colon cancer cell lines HCT116 and SW620 is associated with activation of c-Jun NH2 terminal 
kinase (JNK) [25]. The PI3K pathway mediates cell cycle progression and cell survival through 
downstream effector proteins, one of which is the protein kinase Akt. It is widely accepted that Akt 
plays a crucial role in controlling cell survival and apoptosis in cancer cells. It is activated by insulin or 
growth factors and promotes cell survival by inactivating multiple targets including Bad, caspase-9, 
and forkhead transcription factors. There is a growing body of evidence describing its role in 
promoting cell transformation and tumorigenesis. 1,4-phenylenebis(methylene)selenocyanate (p-XSC) 
(Figure 2) induced apoptosis in androgen responsive LNCaP and androgen-independent LNCaP C4-2 
human prostate cancer cells by decreasing Akt phosphorylation [26]. The Akt3 signaling pathway plays a 
central role in deregulating apoptosis to promote development of approximately 70% of melanomas. 
Nguyen et al. [27] have reported a structurally related compound, 4-phenylbutylisoselenocyanate  
(ISC-4) (Figure 2) that decreased Akt3 signaling and led to a 3-fold increase in apoptosis rates. Later, 
in a nude mouse model injected with wild-type HT-29 colon cancer cells, ISC-4 was shown to inhibit 
tumor growth significantly via the inhibition of Akt, which was more pronounced in culture cells than 
others Akt inhibitors [28]. There have been other reports showing Se compounds with selenocyanate 
moiety to act as Akt modulators. For example, some isatin analogs (Figure 2) containing a 
selenocyanate group in the alkyl chain may be promising compounds induced apoptosis in breast 
cancer cells, accompanied of inhibition of tubulin polymerization and a light effect in Akt 
phosphorylation [29]. Other chemical forms of Se, such as sodium selenite, are able to downregulate  
β-catenin signaling pathway through inhibiting Akt kinase in colorectal cancer cells and colon 
xenograft tumors. Selenite could induce apoptosis in colorectal cancer cells through inhibiting  
Akt/β-catenin survival axis in a ROS-dependent manner [30]. Recently, our research group has 
described that the 3,5-dimethoxyphenyl and 4-cyanophenyl methylseleno imidocarbamates (Figure 2) 
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in the prostate cancer cell (PC-3) caused an important inhibitory effect in Akt and ERK 
phosphorylation, two key nodes in PI3K and mitogen activated protein kinase (MAPK) pathways, 
respectively. Moreover, these compounds also inhibited the action on both mTORC1 and mTORC2, 
implicated in PI3K and MAPK pathways, through the dephosphorylation p70S6K and 4E-BP1 as well 
as Akt on Ser473 in PC-3 cells, thus, emerging as promising inhibitors of the PI3K/Akt/mTOR and 
MAPK pathways [31]. In addition, other quinolinimidoselenocarbamate (EI201) [32] (Figure 2) 
exhibited a strong antitumor activity by multi kinase inhibition with aberrant upregulation of PI3K/Akt 
and MAPK signaling pathways.  
Figure 2. Sodium selenite, 1-4-phenylenebis(methylene)selenocyanate (p-XSC),  
4-phenylbutylisoselenocyanate (ISC-4), 3,5-dimethoxy and 4-cyanophenyl 
imidoselenocarbamates, quinolinimidoselenocarbamate (EI201), 1,3-selenazolin-4-one, 
(1,2-ethanediyl)bisisoselenourea (PBISe), methylselenic acid. 
 
In order to improve the safety for Se compounds, the formulation as nanoparticles is an interesting 
approximation. The encapsulation of Se at nanoparticle size (Nano-Se) upregulates selenoenzyme 
activity efficiently with less toxicity compared with other seleno-compounds. A study carried out  
in LNCaP cancer cells with Nano-Se suggested that Akt catalyzed androgen receptor (AR) 
phosphorylation was a key step for AR ubiquitination by Mdm2 and subsequent degradation by 26S 
proteasome. AR ubiquitination was significantly impaired in Mdm2-deficient mouse embryonic 
fibroblasts (MEFs). It was found in this study that Nano-Se activated Akt by promoting Akt 
phosphorylation at Ser473 and Thr308, which started the downstream AR degradation cascade, 
including phosphorylation and activation of Mdm2, and phosphorylation and polyubiquitination of 
AR. When they used LY294002 to block the PI3K/Akt pathway, the Akt phosphorylation induced by 
Nano-Se was almost disappeared, and Akt regulated Mdm2 phosphorylation was missing too. 
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Furthermore, Nano-Se inhibited prostate cancer cell growth partially by caspase-mediated apoptosis, 
which was through the downregulation of AR expression at both transcriptional and translational 
levels. Nano-Se treatment activated the Akt/Mdm2 pathway, and initiated AR phosphorylation, 
ubiquitination and degradation. The cancer suppression function of Nano-Se consisted of at least two 
mechanisms, regulation of AR transcription and promotion of AR protein degradation [33].  
Among the targets for seleno derivatives are the MAPKs. Several members of the MAPK family 
have been identified, including ERK, SAPK/JNK and p38 MAP kinase. Many subsequent studies have 
confirmed an anti-apoptotic role for ERK1/2 and a pro-apoptotic role for sustained activation of p38 
and JNK. For example, the 1,3-selenazolin-4-one derivatives (Figure 2) induced apoptosis in prostate 
cancer cells (PC-12) through ERK1/2 phosphorylation via MEK activation [34]. Sodium selenite 
treatment in a male Balb/c mice model resulted in increased expression of p38 and JNK MAPK, 
decreased Bcl-2 expression, and increase in caspase-3 expression [35,36]. The Se,Se'-1,4-phenylenebis 
(1,2-ethanediyl)bisisoselenourea (PBISe) (Figure 2) used for topical application retarded melanocytic 
lesion development due to decreased Akt3 signaling, which increased MAP kinase pathway activity 
leading to decreased cell proliferation and increased apoptotic cell death [37]. Cyclin-dependent 
kinases (CDKs) govern the transition between phases during cell cycle progression and therapeutic 
strategies that block CDK activity are therefore unlikely to target tumor cells selectively. It has also 
been seen that in prostate cancer cells (DU-145), MSA acts by upregulation of CDK inhibitors 
(CDKIs) including p16/INK4a, p21/CIP1 and p27/KIP1. These CDKIs bind with their respective 
cyclin/CDK complexes and inhibit the kinase activities of CDK4, CDK6 and CDK2 [38]. One of the 
targets for sodium selenite is protein kinase Cα (PKCα), which is involved in both tumor promotion 
and progression. Moreover, several of the tumor promotion or cancer prevention mechanisms may 
involve redox-sensitive targets. This protein played an antiapoptotic role through its effects on ERK1/2 
and Akt in a study carried out in human leukemia NB4 cells [39]. 
3. Apoptosis and Caspases 
The caspases are a family of cysteine proteases whose main function is the central regulation of cell 
death. Of the 12 caspases that have been identified in humans, 7 transduce apoptotic signals during 
programmed cell death. All caspases are expressed as inactive zymogens (procaspases) and share key 
structural features: an NH2-terminal pro-domain of variable length is followed by a catalytic domain 
consisting of a large (17–20 kDa) subunit and a small (10–12 kDa) subunit. Caspases strongly overlap 
in specificity, and apart from the critical amino acid residues that bind into the catalytic cleft also 
flanking amino acids as well as the tertiary/quaternary structure of the substrate determine the 
efficiency of its cleavage. Caspases can be classified into initiator, such as caspase-2, -8, -9 and -10, 
and executioner caspases, such as caspase-3 and -7. Initiator caspases have a long N-terminal 
prodomain, which mediates the formation of protein complexes that provide the molecular platform for 
caspase activation and inhibition. Initiator caspases cleave a few specific substrates, including 
executioner caspase zymogens. This cleavage activates the executioner caspases, which in turn cleave 
their respective substrates, eliciting apoptotic cell death, with its characteristic morphological features 
of membrane blebbing, pyknotic nuclei, cell rounding and apoptotic vesicle formation. Caspase 
activation can be regulated through an extrinsic or intrinsic signaling pathway. The extrinsic pathway, 
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which involves Fas and tumor necrosis factor receptors (TNFRs) stimulation, activates caspase-8. The 
intrinsic pathway, which may be the primary means of activating apoptotic caspase in mammals, 
triggers the mitochondrial release of cytochrome c (cyt-c), which oligomerizes with Apaf-1 and 
procaspase-9 to form the apoptosome complex. Activated caspase-9 in this complex activates  
caspase-3 to execute apoptosis [40–42] (Figure 3). 
Figure 3. Simplified diagram of molecular pathways that regulate caspase-dependent 
apoptotic cell death. 
 
Among currently identified Se compounds that possess caspase modulation activity, heterocycles 
containing Se represent an important class of small molecules useful in cancer chemotherapy.  
1,2-[Bis(1,2-benzisoselenazolone-3-(2H)-ketone)]ethane (BBSKE) (Figure 4), which is structurally 
related to Ebselen (Figure 4), is a thioredoxin reductase inhibitor that has demonstrated inhibition in 
the growth on the tongue cancer Tca8113 promoting the activity of caspase-3 [43]. Another interesting 
compound with broad spectrum antitumor activity is 2,5-bis(5-hydroxymethyl-2-selenienyl)-3-
hydroxymethyl-N-methylpyrrole (D-501036) (Figure 4) [44]. D-501036 is an apoptotic inducer 
through an increase of the activities of caspase-9 and -3 in a dose and time dependent manner.  
Figure 4. 1,2-[Bis(1,2-benzisoselenazolone-3-(2H)-ketone)]ethane (BBSKE), Ebselen and  
2,5-bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole (D-501036). 
 
Methylseleninic acid (MSA) has been shown to target caspase modulation both alone and  
in combination with other anticancer agents. Li et al. [45] have demonstrated that MSA acts 
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synergistically when combined with tamoxifen in both tamoxifen-sensitive and tamoxifen-resistant 
breast cancer cells through detailed analysis of apoptotic pathways, mainly by sequential activation of 
caspase-9 and then caspase-8. More recently, this practical combination approach was applied to 
improve the efficacy of chemotherapeutic agents, such as ABT-737, a novel small molecule inhibitor 
of Bcl-2 family proteins. MSA acted synergistically with ABT-737 to sensitize aggressive cancer cells 
of human breast (MDA-MB-231), human colon (HT-29) and human prostate (PC-3) to apoptosis 
induction through enhanced caspase-8/-9/-3 activation [46] (Figure 5).  
Figure 5. Signaling pathways underlying ABT-737 and/or Methylseleninic acid (MSA) 
induced apoptosis in cancer cells. 
 
Similar results have been obtained by combination of MSA with paclitaxel for the treatment of 
triple negative breast cancer and mainly the synergism was attributable to more pronounced induction 
of caspase mediated apoptosis [47]. Sodium selenite is another widely studied Se derivative in cancer 
therapy. Selenite has been reported to induce cell death in several types of cells via the mitochondrial 
pathway by a combination of indirect or direct effects with varying contribution of caspases. In 
cervical carcinoma cells, selenite induced caspase-independent apoptosis [48]. When combined with 
docetaxel in prostate cancer cells (PC-3) it significantly increased the proapoptotic factor caspase-3 but 
not with docetaxel alone in monotherapy [49]. These results suggest that the mechanism of apoptotic 
induction may differ between the two cell lines.  
A major class of chemotherapeutic agents used in the treatment of cancer are nucleoside 
derivatives, synthetic compounds that are structurally similar to natural nucleosides. The cytotoxic 
nucleoside derivatives used in cancer chemotherapy, including cytarabine, cladribine, fludarabine, and 
gemcitabine, are phosphorylated by intracellular nucleoside and nucleotide kinases to produce the 
pharmacologically active form related DNA-damaging thymidine nucleoside derivatives. Taking  
in consideration these structures Kim et al. [50] reported the synthesis and cytotoxic effects of  
Int. J. Mol. Sci. 2012, 13 9657 
 
5-phenylselenyl-methyl-2’-deoxyuridine (PhSe-T) and 5-methylselenyl-methyl-2'-deoxyuridine (MeSe-T) 
(Figure 6), as possible new agents for the treatment of human cancer and to elucidate the signaling 
pathway that mediates nucleoside derivatives induced apoptosis in human cancer cells. These 
compounds exhibited apoptotic effects involving caspase-2 and -3 and, to a lesser extent, caspase-8 
and -9. Later, the same authors published a study in HL-60 cells where they suggested that the 
apoptosis induction by PhSe-T and MeSe-T is mediated by the p38 pathway that served as a link 
between ROS generation and DNA damage/caspase activation [51]. Besides, selenous acid (Figure 6) 
and sodium selenite in combination treatment with 5-fluorouracil (5-FU) are able to induce apoptosis 
in certain colorectal cancer cells such as RKO by activation of caspase-8 and -9 [52].  
Figure 6. 5-Phenylselenyl-methyl-2'-deoxyuridine (PhSe-T) and 5-methylselenyl-methyl-2'-
deoxyuridine (MeSe-T), Selenous acid.  
 
4. Apoptosis and Reactive Oxygen Species 
Reactive oxygen species (ROS), such as superoxide anion (O2−), hydrogen peroxide (H2O2), and 
hydroxyl radical (HO·), consist of radical and non-radical oxygen species formed by the partial 
reduction of oxygen. Cellular ROS are generated endogenously as in the process of mitochondrial 
oxidative phosphorylation, or they may arise from interactions with exogenous sources such as 
xenobiotic compounds. When ROS overwhelm the cellular antioxidant defense system, either through 
an increase in ROS levels or a decrease in the cellular antioxidant capacity, oxidative stress occurs. 
Oxidative stress results in direct or indirect ROS-mediated damage of nucleic acids and has also been 
implicated in the inhibition of DNA repair. Not only the excess in ROS levels has the potential to 
contribute to oncogenesis, but high levels of ROS also persist in tumor cells, and can contribute to 
reduced susceptibility to apoptosis. The presence of excess ROS in cancer cells means that tumors 
often exist under mildly oxidative conditions. Because of this heightened basal level, the cancer cells 
become more susceptible to further oxidative stress than normal cells because their endogenous 
antioxidant systems can be overwhelmed. This important biological difference between normal and 
neoplastic cells may potentially be exploited therapeutically by agents that further augment ROS levels 
or weaken antioxidant defenses in cancer cells. The vulnerabilities of cancer cells to oxidative signals 
are now recognized as a potential target for the rational design of new anticancer agents. The overall 
cellular redox state is regulated by three systems, two of which are dependent on glutathione: the 
reduced glutathione (GSH)/oxidized glutathione (GSSG) system; the glutaredoxin (Grx) system; and 
the thioredoxin (Trx)/Trx reductase (TR) system [53,54].  
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4.1. Apoptosis and Glutathione System 
Many of the Se agents in development that modulate redox status or mediate their effects are 
inorganic derivatives. So, the treatment of human oral squamous carcinoma cells (HSC-3) with 
selenium dioxide (SeO2) and sodium selenite induced apoptosis with possible role of glutathione [55]. 
Furthermore, sodium selenite caused cytotoxicity in fish by inducing oxidative stress. The cellular lipid 
peroxidation tends to enhance with increasing selenite exposure dose leading to increase of cell death 
associated with caspase-3/7 activity [56]. A similar behavior was observed with SeMet in the same 
biological model [57]. On the other hand, Chen et al. [58] in a study with three compounds i.e., sodium 
selenite, selenocystamine and diselenodipropionic acid (DSePA) (Figure 7), observed provoked 
oxidation of glutathione with superoxide generation suggesting that the catalytic species producing 
superoxide were the GSSe− or RSe− anion. In 2010, our research group described the biological 
evaluation of a library of 59 organoselenium compounds as superoxide generators. Among them, the 
compound bis(4-aminophenyl)diselenide (Figure 7) showed apoptogenic effect mediated by ROS in 
lymphocytic leukemia cells (CCRF-CEM) [59]. Later, Kunwar et al. [60] demonstrated that DSePA 
exhibited protective effects in albino mice exposed to whole body gamma radiation, implicating the 
maintenance of antioxidant enzymes to be the mechanism of action. Sodium selenite and MSA have 
also been shown to induce ROS in human high metastatic large cell lung cancer cell line L9981 [61]. 
These same authors have published the potential of MSA as an antioxidant which scavenged ROS and 
maintained the stability of redox status in two human lung cancer cell lines, L9981 and 95D, showing 
anticancer effect and apoptosis detection [62]. Other relevant mechanism implicated in the control of 
the redox balance is mediated, to a large extent, by selenoproteins that contain Se in form of 
selenocysteine (SeCys) (Figure 7) within their active site, which might be directly responsible for 
apoptosis induction. [63].  
Figure 7. Selenocystamine, diselenodipropionic acid (DSePA), bis(4-aminophenyl)diselenide, 
selenocysteine (SeCys).  
 
4.2. Apoptosis and Thioredoxin System 
Thioredoxin reductase (TR) is a selenoprotein that functions to reduce the oxidoreductase 
thioredoxin (Trx) in a NADPH-independent manner. This Trx system is an important regulator of 
cellular redox status. TR is also involved in cell proliferation, DNA replication, cell cycle, 
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transcription factor regulation, and other redox-sensitive cell signaling pathways. TR contains Se in the 
form of selenocysteine as the penultimate residue at the C-terminus. In humans, TR is found in all 
tissues and is expressed as two major isoforms: cytosolic (Trx-1) and mitochondrial. Trx-1 is 
overexpressed in many human tumors and it is associated with aggressive tumor growth and decreased 
patient survival. Poerschke et al. [64] studied the behavior of six seleno derivatives,  
2-butylselenazolidine-4-(R)-carboxylic acid (BSCA), 2-cyclohexylselenazolidine-4-(R)-carboxylic 
acid (ChSCA) (Figure 8), SeCys, MSA, p-XSC and SeMet, in lung cancer cells (A549) and observed 
that Trx-1 modulated the cytotoxic effects of BSCA, ChSCA and SeCys by modulation of mitochondrial 
dysfunction. Similar effects were observed in colon cancer cells (RKO) with SeMet, p-XSC, and 
MSA, particularly for the last one. MSA displayed increased cytotoxicity when Trx-1 levels were  
reduced [65]. Taking the aforementioned into account, Trx-1 is considered to be an important 
anticancer drug target and to be involved in both carcinogenesis and cancer progression. Recently, 
ethaselen (before BBSKE) was identified as the first Se-containing inhibitor of mammalian Trx-1 [66]. 
Moreover, the addition of Se, for example as selenite, can enhance the cell sensitivity toward some 
chemotherapeutic agents, such as acylfulvenes or illudin S by inhibition of Trx-1 [67]. Mammalian TR 
isoforms have broad substrate specificity, reducing not only thioredoxins but also inorganic and 
organic Se compounds. Therefore, Se compounds can be substrates of TR and the introduction of a 
substituent group in a non-substituted Se molecule can modify its biochemical and pharmacological 
properties, including its interaction with thiols and its reduction by TR. So, de Souza et al. [68] 
evaluated the potential influence of different radical substituent on the antioxidant capacity of β-selenium 
amine compounds (Figure 8) and how these structural modifications could influence in their activities 
functioning as synthetic mimetic of antioxidant enzymes of mammalian organisms. Gundimeda et al. [69] 
have also suggested that the employment of Se compounds, for example MSA, with agents that target 
TRx-1 could increase the effectiveness or decrease the resistant on malignant cells [70]. Moreover, 
interdependence between the Se status of the selenoprotein GPx2 and sulforaphane (SFN) (Figure 8) 
was observed in experimental colon cancer indicating that both of them may act cooperatively [71].  
Figure 8. 2-Buthylselenazolidine-4-(R)-carboxylic acid (BSCA), 2-cyclohexylselenazolidine- 
4-(R)-carboxylic acid (ChSCa), beta-selenium amine derivatives, sulforaphane. 
 
5. Apoptosis and p53 Regulation 
The p53 protein is a homotetrameric transcription factor that regulates expression of a wide variety 
of genes through direct binding to response elements in DNA. The best understood function of p53 is 
to respond to an array of cellular stresses, such as DNA damage, oncogene expression, nucleotide 
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depletion, and aberrant growth signals by inducing cell cycle arrest, DNA repair, differentiation, 
senescence, or apoptosis. The p53 protein senses and integrates these various stresses via a panoply of 
post-translational modifications, including phosphorylation, acetylation, and ubiquitination. p53 
protein is expressed constitutively, but levels are normally kept low by its rapid ubiquitination by the 
HDM2 protein and rapid proteasomal degradation. Following DNA damage and other stresses, the 
human p53 N-terminal region is phosphorylated. The phosphorylation of p53 disrupts its binding with 
HDM2, blocks ubiquitination and proteolysis, and results in a rapid increase in p53 protein levels, 
allowing p53 to enter the nucleus, bind to DNA and induce expression of DNA repair and cell cycle 
inhibitor genes. Thus, p53 facilitates the repair and survival of damaged cells or eliminates severely 
damaged cells from the replicative pool to protect the organism. Selenoprotein W (SEPW1) is a highly 
conserved small thioredoxin-like protein required for cell cycle progression. In a study carried out in 
breast cancer cells (MCF-7) SEPW1 controlled p21 by modulating levels of the p53 transcription 
factor [72]. It is well known that metal complexes have been one of the most widely employed 
anticancer drugs. The complexation of Se compounds with different transition metals as antitumoral 
agents has been reported in the literature [73]. Later, these authors [74] investigated the mechanism of 
antiproliferative activity of these compounds and concluded that they induced apoptosis, provoked 
changes in cell cycle distribution, caspase-3 activation and activation of the p53 tumor suppressor gene 
family p73. Other organoselenium derivatives, such as PBISe, induced apoptosis in human non-small 
cell lung cancer with significantly enhanced levels of p53 [75]. On the other hand, SeCys in human 
breast carcinoma cells (MCF-7) provoked apoptosis with involvement of p53 phosphorylation and 
ROS generation [76]. In addition, several well-known inorganic forms of Se, such as sodium selenite, 
implicated to p53 in apoptotic processes in vitro against acute promyelocytic leukemia cells (NB4) [77] 
as well as in prostate cancer cells (LNCaP) [78]. 
6. Apoptosis and Miscellaneous Mechanisms and Structures 
It is well known that apoptotic cascades can be triggered by either extrinsic receptor-mediated, 
intrinsic mitochondria-mediated or endoplasmic reticulum (ER) stress-mediated signaling pathways. 
Se induces cellular apoptosis, presumably by acting on the functions of many intracellular proteins 
important for these apoptotic cascades. In addition, depending on the form, Se compounds can target 
separate pathways and the existence of diverse responses for the same chemical structure suggest 
several mechanisms of action and targets [79]. In an experiment comparing the apoptotic mechanisms 
of the Se compounds MeSeCys, SeMet and sodium selenite in four cell lines from human oral 
squamous cell carcinoma (HSC-3 and HSC-4), human non-small cell lung adenocarcinoma (A549) and 
human breast cancer (MCF-7), showed a different response based on the both the compound and the 
cell line used. SeMet increased apoptotic cells in a p53 dependent manner in A549 whereas MeSeCys 
increased apoptotic cells in HSC-3 with high activities of caspase-3, -8 and -9. On the other hand, 
sodium selenite and MeSeCys reduced phosphorylated Akt levels [80].  
The heteropoly complex (C2H10N2)5(NH4)4H2[Se2W10V8O62]·9H2O (SeWV) exhibited apoptotic 
response in K562 cells with accumulation of ROS, reduction of pH and mitochondrial membrane 
potential, significant inhibition of the expression of Bcl-2 and changes in cell cycle phases [81]. The 
structural modification of SeWV to corresponding (NH4)4H4[Se2Mo2V4O24]·7H2O (SeMoV), led to a 
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better antitumor activity and its mechanism was attributed partially to apoptosis with elevation of ROS 
concentration [82].  
The organic compound SeMeCys sensitized renal cancer cells through TRAIL mediated 
downregulation of Bcl-2 [83]. Unfortunately, many cancers develop resistance to TRAIL and for this 
reason TRAIL sensitising agents are currently being explored. One of the strategies used to achieve 
this aim was the development of Se formulation as cyclodextrins. So 2-selenium-bridged β-cyclodextrin 
(2-SeCD) (Figure 9), an organoselenium compound with glutathione peroxidase mimetic activity 
showed reduction in the viability of MDA-MB-468 and T47D breast carcinoma cells through induction 
of the expression of TRAIL both in vitro and in vivo [84].  
Figure 9. 2-Selenium-bridged β-cyclodextrin (2-SeCD), diphenylmethyl selenocyanate, 
temozolomide-selenium (TMZ-Se).  
 
Another strategy is the incorporation of Se to organic forms, such as bonded to polysaccharide. 
Shang et al. [85] prepared a Se containing polysaccharide (SeGLP-2B-1) from Ganoderma lucidum 
with antiproliferative activity against six cancer cell lines in vitro. Later, these authors [86] 
investigated its antitumor mechanism in a study carried out with MCF-7 cell line. They demonstrated 
the apoptotic effect of SeGLP-2B-1 with disruption of the mitochondrial membrane potential followed 
by an increase in the cytochrome c cytosolic levels, and an increase in the activities of caspases 9  
and 3. Furthermore, it has been shown that the Se enrichment of broccoli sprout extract enhances its 
anticancer properties. In a study with human prostate cancer cell line (LNCaP), this extract inhibited 
cell proliferation with apoptosis induction and downregulation of the Akt/mTOR survival pathway [87]. 
Similar effects were observed with Se enriched garlic or organoselenium compounds that provided 
more potent protection against mammary carcinogenesis in rats and greater inhibition of ROS and 
apoptosis induction in breast cancer cells in culture, than natural garlic or the respective organosulfur 
analogues [88]. 
In recent years the combination of Se with widely studied chemotherapeutic agents is being studied. 
So, genistein-selenium combination (Gn-Se) significantly inhibited growth of LNCaP and PC-3  
cells through caspase dependent apoptosis induction with evidence of an alternative non-caspase  
pathway [89]. On the other hand, the therapeutic efficacy of irinotecan is augmented in combination 
with MeSeCys probably due to an increase in the intra-tumor concentrations of SN-38, an active 
metabolite of irinotecan, and significantly increased the apoptosis incidence when compared to 
irinotecan alone [90]. Also, it was observed that when cyclophosphamide (CP) was administered with 
diphenylmethyl selenocyanate (Figure 9), the Se derivative restored the levels of antioxidant enzymes 
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system and resulted in significant tumor growth regression along with upregulation of apoptosis and 
reduction of cellular toxicity of CP simultaneously improving its antitumor efficacy [91]. Other 
possibility is the rational incorporation of Se into molecules with recognized efficacy in cancer. An 
example is temozolomide (TMZ) that is widely used in the treatment of human malignancies such as 
glioma and melanoma. Cheng et al. [92] synthesized a new TMZ selenium analog (TMZ-Se) (Figure 9) 
by introducing of an N-ethylselenocyanate extension to the amide functionality in TMZ structure. The 
introduction of Se into TMZ produced superior cytotoxicity to TMZ in human glioma and melanoma 
cells. Furthermore, this compound caused a greater DNA damage response, more severe impairment of 
mTOR signaling, was more apoptogenic than TMZ in tumor cells, and as a novelty induced greater 
autophagic response. 
Moreover, Se is able to revert the carcinogenic effects induced by azoxymethane and dextran 
sodium sulfate on colon carcinogenesis in a mouse model with high iron diet. In a study carried out 
with five experimental groups the incidence of colon tumor formation in the high Se diet group was 
19% lower than control and the apoptotic index was significantly higher than other groups [93].  
7. Apoptosis versus Autophagy 
Autophagy is a type of programmed cell death alternative to apoptosis and recent studies have 
established that it also plays an important role in cancer biology. However, exactly how autophagy 
intersects with cancer development, disease progression, and therapeutic response is controversial. The 
relationship between autophagy and apoptosis is complex and varies with cell types and the specific 
stress placed upon the cell. While the molecular mechanisms leading to apoptosis have been elucidated 
to some extent during the past 15 years, autophagic cell death is not well characterized at the molecular 
level yet. Expanding the knowledge of the molecular cross-talk among pathways that regulate tumor 
cell death is crucial in guiding the successful design of future anticancer therapeutics. Apoptosis and 
autophagy can act as partners to induce cell death in a coordinated or cooperative fashion. Autophagy 
proteins can also play a role in cellular events that occur during apoptosis. For example, Atg5 may be 
an independent key player in both apoptosis and autophagy. The low levels of Atg5 cleavage product 
may have significant effects on apoptosis, but not the intact Atg5 that participates in autophagy. Bcl-2 
phosphorylation may not only be a mechanism for regulating apoptosis and a mechanism for 
regulating autophagy, but perhaps also a mechanism for regulating the switch between the two 
pathways. JNK is able to trigger autophagy by targeting Bcl-2/Bcl-xL proteins and abrogating their 
binding to Beclin 1. Recently, Beclin 1 has been shown to be among the substrates of death-associated 
protein kinase (DAPK), a proapoptotic serine/threonine kinase, and its phosphorylation reduces its 
binding to the Bcl-2 family members, thus suggesting a possible mechanism by which DAPK may also 
induce autophagy. A complex role in the regulation of autophagy is played by p53, one of the most 
important tumor suppressor proteins. In fact, p53 regulates autophagy both in a positive and in a 
negative fashion, depending on its subcellular localization [39]. p53 and damage-regulated autophagy 
modulator (DRAM) can induce accumulation of autophagosomes. In addition, p53 affects autophagy 
by modulating signaling through the mTOR nutrient-sensing kinase which controls autophagy at the 
initiation stage. Inhibition of autophagy leads in most cases to an increased susceptibility to apoptotic 
stimuli. Moreover, a growing number of proteins that play a negative regulatory role in both events 
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have been identified. Autophagy and apoptosis may be triggered by common upstream signals. Recent 
reports have shown that Akt inhibits apoptosis by phosphorylation of the Bcl-2 protein family member, 
Bad, allowing for cell survival. In addition, activation of the PI3K/Akt/mTOR pathway can cause 
inhibitory effects of Akt on apoptosis and mTOR on autophagy and enhance survival capacity in 
neoplastic cells. Therefore, it is likely that induction of apoptotic or autophagic cell death may depend 
on the level of mitochondrial membrane permeabilization. The induction of autophagic cell death may 
be an ideal approach for cancers that are resistant to apoptosis by anticancer therapies [94,95].  
Autophagy has been reported to play a role in the activity of suberoylanilide hydroxamic acid 
(SAHA) (Figure 10) which has emerged as an effective anticancer agent and is recently approved by 
the FDA for the treatment of advanced cutaneous T-cell lymphoma [96]. Mechanistically, SAHA 
regulates autophagy by inducing both LC3 expression transcriptionally and inactivating mTOR, which 
might be indirect or not at all related to transcription [97]. Hystone deacetylase (HDAC) inhibitors are 
emerging as potent anticancer agents that can reactivate gene expression and restore the capability of 
malignant cells to undergo programmed cell death and are able to mediate the induction of both 
apoptosis and autophagy [94]. Desai et al. [98] have synthesized several Se containing analogs of 
SAHA and have studied its mechanism of action demonstrating that they act as HDAC inhibitors. Among 
the reported derivatives, bis(5-phenylcarbamoylpentyl) diselenide (SelSA-1) and 5-phenylcarbamoylpentyl 
selenocyanide (SelSA-2) (Figure 10) are significantly more effective in inducing cytotoxicity (in H460 
and H441 cells), in the inhibition of MAPK signaling and in the induction of autophagy in lung cancer 
cells (A549 cells) than SAHA [99].  
Figure 10. Suberoylanilide hydroxamic acid (SAHA), bis(5-phenylcarbamoylpentyl) 
diselenide (SelSA-1), phenylcarbamoylpentyl selenocyanide (SelSA-2).  
 
8. Selenium, Cancer and Cell Death Types: Conclusions, Paradox and Perspectives  
Our understanding of the significance of Se in cancer therapy and cell death has expanded greatly in 
recent years. In this review we have summarized information on more than 100 references, most of 
which were published in last three years, because our research team had published a review article in 
2008 related to Se and apoptosis [100]. This list of compounds and references is by no means 
exhaustive and merely hints at the hundreds of other citations due to the ever-increasing amount of 
work carried out in this field. Numerous studies and strategies have been suggested for application of 
Se in cancer including the utilization of Se in combination with other therapies. For example, Se 
enhances the antitumor effects of photodynamic therapy (PDT) in TC-1 tumor cells and implanted 
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mice [101]. Also, the modulation of the GSH system mediated by the expression of different factors 
such as Trx1/p38(MAPK)p53 signaling pathway [102] or a decrease in the expression of Se binding 
protein 1 (SBPI) that could be a novel biomarker for predicting prognosis and guiding personalized 
therapeutic strategies, especially in patients with advanced hepatocellular carcinoma (HCC) [103]. One 
of the problems of the use of Se is the narrow margin between toxic amounts and the amounts needed 
for dietary requirements or therapeutic effects. In order to solve these limitations Nano-Se had 
significantly lower toxicity, without compromising the important therapeutic capacities [104]. On  
the other hand, the practical use of Se and seleno compounds, such as SeO32−, MSA, SeMet, and 
selenocystine is extendable to the treatment of illness caused by parasites derived from Plasmodium by 
inducing apoptosis-like cell death with involvement of ROS [105]. It is interesting to point out that the 
effectiveness of certain molecules as both anticancer drugs and antiprotozoal agents suggested that this 
class of compounds and their derivatives might be useful for both the diseases [106–108]. 
In spite of the aforementioned and of the importance of Se in control disturbances in the redox state 
of sick cells for therapeutic advantage in cancer treatment, there are evidences from numerous clinical 
and experimental studies that have shown that the antioxidant activities of similar Se-containing 
compounds are not identical, suggesting that each compound must be examined individually for its 
antioxidant behavior [109,110]. For these reasons, there are contradictory literature reports of their 
efficacy. Brozmanova et al. [7] explained the broad interest to exploit the positive effects of Se  
on human health and cancer therapy and have studied the negative effects such as toxicity and  
DNA damage induction resulting from high Se intake. These results have been corroborated by  
Lee et al. [111]. An overdose of Se generates oxygen radicals and leads to apoptotic cell death by 
inducing oxidation and cross linking of protein thiol groups essential for cell survival. Based on the 
results from the biological studies it is evident that Se seems to have both harmful and beneficial 
attributes and by a simple modification in the structure, new potent analogues with high therapeutic 
index and the desired anticancer and apoptotic activities can be generated. Further studies are 
warranted to pinpoint the structural requirements of Se compounds necessary for maximum efficacy 
and to explore the true potential of this promising dietary trace element.  
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